Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed with or without PF-3512676 in previously treated advanced non-small cell lung cancer
2006-001588-52Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jun 2006
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of agatolimod in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival. Started Jun 2006; status: terminated.
02
Drugs
agatolimod
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-001588-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001588-52.